ITS Interim

 
Fund Quotes for ITS Interim top ^
  • Category: Short Government
  • Morningstar Rating: 3 Stars
Sign-up for sfitx investment picks

 
News Articles for ITS Interim top ^
Orion Engineered Carbons S.A. (NYSE:OEC), a worldwide supplier of specialty and high-performance Carbon Black, today announced that its board of directors has declared an interim dividend of €0.67 * per common share, equivalent to a total distribution of €40 million.
Sign-up for Orion Engineered Carbons Announces Interim Cash Dividend investment picks
2014/10/30
THE HAGUE, The Netherlands , October 30, 2014 /PRNewswire/ -- The Board of Royal Dutch Shell plc ("RDS") (NYSE:RDS.A) (NYSE:RDS.B) today announced an interim dividend in respect of the third quarter of 2014 of US$0.47 per A ordinary share ("A Share") and B ordinary share ("B Share"), an increase of US$ 0.02 on the equivalent US dollar dividend for the same quarter last year.
Sign-up for Royal Dutch Shell plc Third Quarter 2014 Interim Dividend investment picks
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) today announced updated interim results from its ongoing ARMOR2 Phase 2 clinical trial of galeterone in castration-resistant prostate cancer (CRPC) patients.
Sign-up for Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) Including Those Showing a Variant Form of Prostate Cancer Resistant to Hormone Therapy investment picks
2014/10/30
THE HAGUE, The Netherlands , October 30, 2014 /PRNewswire/ -- The Board of Royal Dutch Shell plc (NYSE:RDS.A) (NYSE: RDS.B) today announced the intended timetable for the 2015 quarterly interim dividends.
Sign-up for Royal Dutch Shell Plc 2015 Interim Dividend Timetable investment picks
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and the treatment of localized prostate cancer, today announced findings from an administrative interim analysis of efficacy in its ongoing Phase 3 “PLUS-1” trial of PRX302 as a treatment for lower urinary tract symptoms of BPH.
Sign-up for Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia investment picks
By Michael Calia Carlin Adrianopoli of FTI Consulting to take over as struggling chain's interim finance chief RadioShack Corp.
Sign-up for RadioShack hires advisory firm, which comes with interim CFO investment picks
MGE Energy, Inc. (Nasdaq: MGEE) today published its investor newsletter "Interim Report" with the following topics: - Rate changes - Third-quarter earnings reported - Investor tax information - Lobbying reports available online - Natural gas extensions The newsletter is available on MGE Energy's website at: http://www.mgeenergy.com/interimreport Interim Report is published quarterly to provide investors with information about MGE Energy and its primary subsidiary, Madison Gas and Electric.
Sign-up for MGE Energy Issues December 2014 'Interim Report' investment picks
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that updated, interim results from the company’s ongoing Phase 2 clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer (CRPC) will be presented at the 26 th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held November 18-21 in Barcelona, Spain.
Sign-up for Tokai Pharmaceuticals Announces Interim Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer to be Presented at the EORTC-NCI-AACR Symposium investment picks
-- Interim Data Suggest Improved Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin®) --
Sign-up for VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma at 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) investment picks
HOUSTON and LONDON , Nov.
Sign-up for LyondellBasell Board Authorizes Interim Dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162755&ProfileId=051205&sourceType=1 STOCKPORT, UNITED KINGDOM --
Sign-up for API Group plc ("API" or the "Group") Announces Interim Results investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.
Sign-up for Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CTRC-AACR San Antonio Breast Cancer Symposium investment picks
2014/12/22
Vicwest Inc. Obtains Interim Order and Announces Special Meeting in connection with its Previously-Announced Agreement to be Acquired for $12.70 Per Share Canada NewsWire OAKVILLE, ON , Dec.
Sign-up for Vicwest Inc. Obtains Interim Order and Announces Special Meeting in connection with its Previously-Announced Agreement to be Acquired for $12.70 Per Share investment picks
2014/10/30
SAN DIEGO and TORONTO , Oct.
Sign-up for Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157613&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM --
Sign-up for Anglo Pacific Group PLC Interim Management Statement investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Sign-up for Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting® investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ITS Interim
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Istar Financial  |  Next: Ivanhoe Energy